



Financial Tear Sheet

Corporate Profile

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, L.L.C. and Cypress Pharmaceuticals, Inc.

Primary IR Contact

Bob Yedid
LifeSci Advisors
Phone: 646-597-6989
Fax: 516-428-8577
E-mail:
Bob@lifesciadvisors.com

Stock Information

PTX.O (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$2.44
Change (%)	▲ 0.01 (0.41%)
Volume	29,791
52 Week Low	\$2.00
Market Cap	\$28,793,388
Rolling EPS	-6.14
PE Ratio	0
Shares Outstanding	11,873,562

Data as of 07/17/18 3:59 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releases & Upcoming Events

June 22, 2018 - 8:00 a.m.

Pernix Therapeutics Announces Result of Bid Process for Acquisition of Worldwide Rights to Contrave® for Weight Loss

May 10, 2018 - 4:01 p.m.

Pernix Therapeutics Reports First Quarter 2018 Financial Results

May 1, 2018 - 4:06 p.m.

Pernix Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 10

There are currently no events scheduled.

SEC Filings

Filing Date	Form
06/22/18	8-K
05/23/18	4
05/23/18	4
05/23/18	4

Executive Leadership Team

John Sedor	Chairman of the Board and CEO
Kenneth R. Piña	Senior Vice President, Chief Legal & Compliance Officer and Corporate Secretary
Angus Smith	Senior Vice President, Chief Business Officer and Principal Financial Officer
Christopher J. Bordiuk	Vice President of Human Resources
George P. Jones	Vice President of Sales and Marketing
Anthony M. Orrico	Vice President of Technical and Supply Operations
Glenn Whaley	Vice President of Finance, Principal Accounting Officer and Corporate Controller